患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

ENGLISH
国立保健医療科学院
クリップした情報
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

削除
治験例

海外の治験の状況「1」での検索結果

絞り込み

2144件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  

  • Recruiting

  • Sahlgrenska Cardiomyopathy Project
  • Dilated Cardiomyopathies;Hypertrophic Cardiomyopathy;Restrictive Cardiomyopathy;Arrhythmogenic Right Ventricular Cardiomyopathy;Myocarditis;Sarcoidosis With Myocarditis;Giant Cell Myocarditis;Amyloidosis; Heart (Manifestation)
  • Sweden
  • 2018-04-23

  • Recruiting

  • ADDIA Proof-of-Performance Clinical Study
  • Alzheimer Disease (AD);Frontotemporal Lobar Degeneration;Dementia With Lewy Bodies (DLB);Parkinson Disease Dementia (PDD);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)
  • Belgium, France, Italy, Switzerland, Turkey
  • 2017-01-23

  • Recruiting

  • Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
  • Diffuse Astrocytoma;Anaplastic Astrocytoma;Astrocytoma;Oligodendroglioma, Childhood;Anaplastic Oligodendroglioma;Glioblastoma;Pilocytic Astrocytoma;Giant Cell Astrocytoma;Pleomorphic Xanthoastrocytoma;Anaplastic Pleomorphic Xanthoastrocytoma;Angiocentric Glioma;Chordoid Glioma of Third Ventricle;Gangliocytoma;Ganglioglioma;Anaplastic Ganglioglioma;Dysplastic Gangliocytoma of Cerebrellum;Desmoplastic Infantile Astrocytoma and Ganglioglioma;Papillary Glioneuronal Tumor;Rosette-forming Glioneurona Tumor;Central Neurocytoma;Extraventricular Neurocytoma;Cerebellar Iponeurocytoma
  • Argentina, Australia, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States
  • 2016-02-04

  • Recruiting

  • Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
  • Adenovirus;Anesthesia;Anxiety;Anxiolysis;Autism;Autistic Disorder;Bacterial Meningitis;Bacterial Septicemia;Benzodiazepine;Bipolar Disorder;Bone and Joint Infections;Central Nervous System Infections;Convulsions;Cytomegalovirus Retinitis;Early-onset Schizophrenia Spectrum Disorders;Epilepsy;General Anesthesia;Gynecologic Infections;Herpes Simplex Virus;Infantile Hemangioma;Infection;Inflammation;Inflammatory Conditions;Intra-abdominal Infections;Lower Respiratory Tract Infections;Migraines;Pain;Pneumonia;Schizophrenia;Sedation;Seizures;Skeletal Muscle Spasms;Skin and Skin-structure Infections;Treatment-resistant Schizophrenia;Urinary Tract Infections;Withdrawal;Sepsis;Gram-negative Infection;Bradycardia;Cardiac Arrest;Cardiac Arrhythmia;Staphylococcal Infections;Nosocomial Pneumonia;Neuromuscular Blockade;Methicillin Resistant Staphylococcus Aureus;Endocarditis;Neutropenia;Headache;Fibrinolytic Bleeding;Pulmonary Arterial Hypertension;CMV Retinitis;Hypertension;Chronic Kidney Diseases;Hyperaldosteronism;Hypokalemia;Heart Failure;Hemophilia;Heavy Menstrual Bleeding;Insomnia
  • Australia, Canada, Israel, Singapore, United Kingdom, United States
  • 2011-08-17

  • Recruiting

  • The Swedish BioFINDER 2 Study
  • Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment;Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment;Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment
  • Sweden
  • 2017-05-28

  • Recruiting

  • Long-term outcome of patients with inherited metabolic diseases after diagnosis by expanded newborn screening
  • Maple syrup urine disease (MSUD) Glutaric aciduria type I (GA1) Isovaleric aciduria (IVA) Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) Long-chain acyl-CoA dehydrogenase deficiency (VLCADD) Long-chain hydroxy-Acyl-CoA dehydrogenase deficiency (LCHADD) Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine palmitoyltransferase II deficiency (CPT II) Carnitine translocase deficiency (CACT) Phenylketonuria (PKU) Biotinidase deficiency Tyrosinaemia type I Classical homocystinuria (CBS deficiency) Methylmalonic aciduria (incl. mutase deficiency [mut0, mut-], CblA und CblB defect) Combined methylmalonic aciduria and hyperhomocysteinaemia and accordingly isolated remethylation disorders due to inherited defects of cobalamin metabolism (incl. Transcobalamin-II deficiency, CblC, CblD, CblE, CblF, CblG, CblJ and CblX defects) Methylenetetrahydrofolate reductase (MTHFR) deficiency Congenital cobalamin deficiency (due to maternal cobalamin deficiency) Propionic aciduria (PA) Urea-cycle defects (NAGS deficiency, CPS1 deficiency, OTC deficiency, Citrullinaemia, Argininosuccinic aciduria, Argininaemia, HHH syndrome) Multiple acyl-CoA Dehydrogenase deficiency HMG-CoA lyase deficiency Carnitine transporter deficiency
  • Germany
  • 2018-01-12

  • Recruiting

  • Network for Early Onset Cystic Kidney Diseases
  • ;Q61.1 - Polycystic kidney, autosomal recessive;Q61.3 - Polycystic kidney, unspecified;Q61.8 - Other cystic kidney diseases;Q61.9 - Cystic kidney disease, unspecified;Q87.5 - Other congenital malformation syndromes with other skeletal changes;Q87.8 - Other specified congenital malformation syndromes, not elsewhere classified;Q77.2 - Short rib syndrome;Q77.6 - Chondroectodermal dysplasia;Q77.9 - Osteochondrodysplasia with defects of growth of tubular bones and spine, unspecified
  • Austria, Germany, Switzerland
  • 2016-09-06

  • Recruiting

  • Epidemiological cross-sectional study on the impact of malocclusion and habits on oral health and quality of life
  • ;K02.0 - Caries limited to enamel;K07.0 - Major anomalies of jaw size;K07.1 - Anomalies of jaw-cranial base relationship;K07.2 - Anomalies of dental arch relationship;K07.3 - Anomalies of tooth position;K07.4 - Malocclusion, unspecified;K07.5 - Dentofacial functional abnormalities;K07.6 - Temporomandibular joint disorders;K07.8 - Other dentofacial anomalies;K05.0 - Acute gingivitis;K05.1 - Chronic gingivitis;K05.2 - Acute periodontitis;K05.3 - Chronic periodontitis;K05.4 - Periodontosis;K03.0 - Excessive attrition of teeth;K03.1 - Abrasion of teeth;K03.2 - Erosion of teeth;K03.6 - Deposits [accretions] on teeth;K03.7 - Posteruptive colour changes of dental hard tissues;K03.8 - Other specified diseases of hard tissues of teeth;K13.1 - Cheek and lip biting;K13.2 - Leukoplakia and other disturbances of oral epithelium, including tongue;K13.3 - Hairy leukoplakia;K13.4 - Granuloma and granuloma-like lesions of oral mucosa;K13.5 - Oral submucous fibrosis;K13.6 - Irritative hyperplasia of oral mucosa;K13.7 - Other and unspecified lesions of oral mucosa;F99 - Mental disorder, not otherwise specified
  • Germany
  • 2017-02-08

  • Recruiting

  • Mayo AVC Registry and Biobank
  • Arrhythmogenic Right Ventricular Cardiomyopathy;Cardiomyopathies;Heart Diseases;Cardiovascular Diseases;Sudden Cardiac Arrest;Sudden Cardiac Death;Arrhythmogenic Right Ventricular Dysplasia;Arrhythmogenic Ventricular Cardiomyopathy;Familial Dilated Cardiomyopathy;Cardiovascular Abnormalities;Sarcoidosis;Cardiac Arrhythmia;Cardiac Sarcoidosis;Myocarditis;Inflammatory Cardiomyopathy;Ventricular Tachycardia;Right Ventricular Outflow Tract Ventricular Tachycardia;Arrhythmogenic Right Ventricular Cardiomyopathy;Cardiomyopathies;Heart Diseases;Cardiovascular Diseases;Sudden Cardiac Arrest;Sudden Cardiac Death;Arrhythmogenic Right Ventricular Dysplasia;Arrhythmogenic Ventricular Cardiomyopathy;Familial Dilated Cardiomyopathy;Cardiovascular Abnormalities;Sarcoidosis;Cardiac Arrhythmia;Cardiac Sarcoidosis;Myocarditis;Inflammatory Cardiomyopathy;Ventricular Tachycardia;Right Ventricular Outflow Tract Ventricular Tachycardia
  • United Kingdom, United States
  • 2017-01-30

  • Recruiting

  • Treatment of cutaneous leishmaniasis with pentamidine isethionate in Suriname; a comparison study between two treatment regimes, 3 days vs 7 days.
  • The disease leishmaniasis, caused by protozoan Leishmania parasites and transmitted via infected female sandflies and reservoir hosts is endemic in 88 countries and 350 million people are at risk. Leishmaniasis prevalence is >12 million cases/year and the incidence is >2.5 million cases/year. The estimated disease burden is 2.4 million DALYs. Leishmaniasis is a category 1 disease (Emerging or uncontrolled diseases) and the World Health Organization (WHO) has acknowledged it as a severely neglected disease and urged intensified research programs to improve vector control, diagnostics and therapeutic arsenal to contain further incidence and morbidity. An infection with Leishmania parasites can, depending of the infecting species, give rise to several distinct clinical manifestations, ranging from localized cutaneous leishmaniasis (CL) with single to multiple skin ulcers, satellite lesions or nodular lymphangitis or possibly mucosal involvement and systemic visceral leishmaniasis (VL) with involvement of different organs (like liver and spleen) and bone marrow, which may be lethal. Currently, Pentamidine isethionate is the only drug available for patients with CL in Suriname. Usual care at this moment in Suriname entails a standard treatment regimen of three doses of 4mg/kg body weight Pentamidine Isethionate im. (in 7 days)
  • The Netherlands
  • 2009-09-25